Prosecution Insights
Last updated: October 04, 2026
Application No. 18/254,315

COMPOUNDS FOR TREATING SEGMENTAL PROGEROID SYNDROMES

Non-Final OA §102
Filed
May 24, 2023
Priority
Nov 24, 2020 — EU 20306430.8 +2 more
Examiner
CHONG, YONG SOO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
École Nationale Supérieure De Chimie De Montpellier
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
6m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
389 granted / 888 resolved
-16.2% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
52 currently pending
Career history
950
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
53.0%
+13.0% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
17.3%
-22.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 888 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Applicant's election with traverse of Group I, drawn to a compound of formula I, and the species election, in the reply filed on 4/21/26 is acknowledged. The traversal is on the grounds that compounds of formula I makes a contribution over the prior art. This is not found persuasive because as shown below, the compounds of formula I do not make a contribution over the prior art. The requirement is still deemed proper and is therefore made FINAL. It is noted that Group II, drawn to a compound of formula II, will not be rejoined with Group I, drawn to a compound of formula I, since Group II is a subset of Group I. Claims 1-17 are pending. Claims 3-7, 9-17 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-2, 8 are examined herein insofar as they read on the elected invention and species (below). PNG media_image1.png 168 470 media_image1.png Greyscale A search has been performed on the elected species, which was found free of the prior art. The search will now be expanded and another species will be selected for examination. With regard to the expanded species selected by examiner for examination, claim 2 has been withdrawn from further consideration as being drawn to a non-elected species. Claims 1 and 8 are examined herein insofar as they read on the elected invention and the expanded species. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Skeggs et al. (“Kinetics of the reaction of renin with nine synthetic peptide substrates,” Journal of Experimental Medicine, 1968, 128, 1, 13-34). Skeggs et al. teach the reaction between renin and nine synthetic peptide substrates (title). The synthesis of the below compound is shown from an aqueous workup (page 20, second full paragraph, analysis: C36H52N4O8). PNG media_image2.png 312 428 media_image2.png Greyscale Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free). /Yong S. Chong/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

May 24, 2023
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734158
APPLICATION OF RILUZOLE- AND BORNEOL-CONTAINING COMPOSITION IN PREPARATION OF MEDICATION FOR TREATING CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 15, 2026
Patent 12721846
METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA
4y 3m to grant Granted Sep 01, 2026
Patent 12714700
METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES
2y 5m to grant Granted Aug 25, 2026
Patent 12691087
METHOD OF ENHANCING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM
7y 1m to grant Granted Jul 28, 2026
Patent 12686657
ANTI-INFLAMMATORY CARBOXAMIDE DERIVATIVES
2y 10m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
85%
With Interview (+41.6%)
3y 10m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 888 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month